Palmitoyl Dopamine

Palmitoyl Dopamine

SCHEMBL30438287

CCCCCCCCCCCCCCCC(=O)NCCc1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 5/20 1.00
MAPT P10636 4/20 1.00
HSD17B10 Q99714 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
HPGD P15428 2/20 0.86
KDM4E B2RXH2 1/20 0.86
NPC1 O15118 1/20 0.86
GMNN O75496 1/20 0.86
USP2 O75604 1/20 0.86
LMNA P02545 1/20 0.86
TP53 P04637 1/20 0.86
CYP1A2 P05177 1/20 0.86
POLB P06746 1/20 0.86
CYP3A4 P08684 1/20 0.86
CYP2C9 P11712 1/20 0.86
IDE P14735 1/20 0.86
ALOX15 P16050 1/20 0.86
NFKB1 P19838 1/20 0.86
MAPK1 P28482 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617723 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30368905 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30718914 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30718949 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
Palmitoyl Dopamine SCHEMBL875454 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30582326 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL10617939 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL3326638 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL3325854 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL671000 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024124172-A1 COMPOSITIONS AND METHODS FOR STIMULATING AND/OR ENHANCING EXERCISE MOTIVATION AND/OR PHYSICAL PERFORMANCE THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-06-13 WO claimed
CN-116742275-A Spongy composite lithium ion battery diaphragm 德州东鸿制膜科技有限公司 2023-09-12 CN claimed
EP-4554560-A1 TOPICAL COMPOSITION AND USES THEREOF Universidade de Coimbra (PT) 2025-05-21 EP disclosed
US-12290549-B2 Method of reducing titers of antibodies specific for a therapeutic agent DUKE UNIVERSITY (US) 2025-05-06 US disclosed
CN-119235833-A Application of N-acyl dopamine family lipid in preventing and treating drug-induced parkinsonism movement complications 暨南大学 2025-01-03 CN disclosed
WO-2024124172-A1 COMPOSITIONS AND METHODS FOR STIMULATING AND/OR ENHANCING EXERCISE MOTIVATION AND/OR PHYSICAL PERFORMANCE THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-06-13 WO disclosed
WO-2024013711-A1 TOPICAL COMPOSITION AND USES THEREOF UNIVERSIDADE DE COIMBRA (PT) 2024-01-18 WO disclosed
CN-116742275-A Spongy composite lithium ion battery diaphragm 德州东鸿制膜科技有限公司 2023-09-12 CN disclosed
US-11694812-B2 Method and system for assessing, quantifying, coding and communicating patient's health and perioperative risk SILVERMAN DAVID G (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12290549-B2 Method of reducing titers of antibodies specific for a therapeutic agent SNRPE, SARNP, RBM17 TRPV1 4707/4885MAPT 876/4885HSD17B10 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.